The Food and Drug Administration (FDA), the US food regulatory authority, has submitted a regulatory proposal for the CBD to the White House Office of Management and Budget (OMB) for review.
The contents of the document, entitled “cannabidiol Enforcement Policy, Draft Guidance to the industry” are not yet publicly available.
This latest filing of recommendations comes after the FDA published distinct guidelines to encourage clinical cannabis research. This document also reviewed by the OMB before it could be published.
It is not yet clear, however, whether the FDA will publish the CBD recommendations document currently under review by White House officials. The agency communicated very little on the CBD since the legalization of hemp at the federal level under the 2018 Farm Bill. It often issued warnings to cannabis companies in many cases, such as when some companies claimed that the CBD could treat or cure coronavirus, and recalled certain products that did not meet food standards.
The FDA also recently submitted a report to Congress on the state of the CBD market, which describes the studies the agency conducted on the content and quality of the cannabis products it has tested over the past six years.
This month, a draft bill released for the FDA, including a provision for “funding to develop a regulatory framework for CBD products.
All of these developments could quickly bring some clarity to the CBD in the US, which is currently shifting between state and federal regulation of cannabis and hemp.